ZIA CP010219-10408 (ZIA) | |||
---|---|---|---|
Title | Serum Markers of Immunity & Risk of Brain tumors | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Berrington, Amy | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $1,274 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Autoimmune Diseases (15.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Brain (100.0%) | ||
Research Type | |||
Cancer-Related Biology
Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
"""The primary objective of the proposed study is to quantify the dose-response relationship between risk of glioma and levels of cytokines/growth factors in serum collected years prior to cancer diagnosis, and to evaluate whether this relationship may account for the inverse association between history of allergy/autoimmune disease and risk of glioma reported in previous studies. All glioma cases in active duty military personal diagnosed between 1988 and 2004 will be identified from the ACTUR database using ICD-O-3 codes. For each case with at least one pre-diagnostic serum sample in the DoDSR, we plan to individually match one glioma-free control randomly selected within the DoDSR strata of sex, race/ethnicity, year of birth (+/- 1 yr), and dates of each serum sample collection (+/- 30 days). Cytokine testing on de-identified serum samples will be done using multiplex assays from Meso Scale Discovery. Data on selected allergic and autoimmune diseases (ICD-9 codes) diagnosed prior to date of glioma diagnosis (or referent date for controls) will be obtained from the Defense Medical Surveillance System database (DMSS).""" |